Embera is developing the first medication that treats addiction by moderating activity in the stress response system.

EMB-001 may potentially reduce the cravings and loss of control that drive addiction by uniquely targeting multiple pathways, to maximize potential efficacy more than either drug used alone. A therapy that breaks these barriers and results in long term abstinence and recovery would be a significant contribution to the treatment of a broad range of addictions.

Media & Publications

,

Embera NeuroTherapeutics Announces Positive Topline Data from Phase 1b Cocaine Interaction Study of EMB-001

/
Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for cocaine, nicotine, and other addictions, today announced that EMB-001 was found to be well-tolerated in a Phase 1b cocaine interaction study, and no new safety signals were observed.
,

New Stress Response Modulation Drug Showing Promise in the Treatment of Addiction

/
Robert Linke, Embera’s president and CEO, spoke with CEOCFO Magazine regarding Embera’s new approach to treating addictions and how attitudes toward addiction are evolving.
,

Embera NeuroTherapeutics Receives $11M Grant from National Institute on Drug Abuse for the Clinical Development of EMB-001 for the treatment of Cocaine Addiction

/
Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for cocaine, nicotine, and other addictions, today announced that it has received an $11.1 million, three-year grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH). The grant will support continued clinical development of EMB-001 for the treatment of cocaine addiction, which is clinically termed “cocaine use disorder.”